Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma
Phase of Trial: Phase IV
Latest Information Update: 06 Feb 2017
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Multiple myeloma; Pneumococcal infections
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Dec 2016 Status changed from active, no longer recruiting to completed.
- 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.